Login to Your Account

Other news to note

Wednesday, November 8, 2017

Eutilex Co. Ltd., of Seoul, said it entered a strategic partnership with Zhejiang Huahai Pharmaceutical Ltd., of Shanghai, which will take a $30 million equity stake in Eutilex and in return receive an exclusive license to develop and commercialize EU-101, a humanized monoclonal antibody for cancer treatment, in the People's Republic of China, Taiwan, Hong Kong and Macau. 

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription